These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12127923)

  • 1. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization.
    Husted SE; Wallentin L; Lagerqvist B; Kontny F; Ståhle E; Swahn E
    Eur Heart J; 2002 Aug; 23(15):1213-8. PubMed ID: 12127923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving outcomes in acute coronary syndromes--the FRISC II trial.
    Kontny F
    Clin Cardiol; 2001 Mar; 24(3 Suppl):I3-7. PubMed ID: 11286312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
    Wallentin L
    Haemostasis; 2000; 30 Suppl 2():108-13; discussion 106-7. PubMed ID: 11251353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
    Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators.
    Lancet; 1999 Aug; 354(9180):701-7. PubMed ID: 10475180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators.
    Lancet; 1999 Aug; 354(9180):708-15. PubMed ID: 10475181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
    Husted S; Kher A
    Ann Med; 2000 Dec; 32 Suppl 1():53-9. PubMed ID: 11209983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial.
    Janzon M; Levin LA; Swahn E;
    Heart; 2003 Mar; 89(3):287-92. PubMed ID: 12591833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.
    Oldgren J; Fellenius C; Boman K; Jansson JH; Nilsson TK; Wallentin L; Siegbahn A
    J Intern Med; 2005 Nov; 258(5):420-7. PubMed ID: 16238677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group.
    Swahn E; Wallentin L
    Am J Cardiol; 1997 Sep; 80(5A):25E-29E. PubMed ID: 9296466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous multilead ST-monitoring identifies patients with unstable coronary artery disease who benefit from extended antithrombotic treatment.
    Jernberg T; Abrahamsson P; Lindahl B; Johanson P; Wallentin L; Dellborg M
    Eur Heart J; 2002 Jul; 23(14):1093-101. PubMed ID: 12090747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II).
    Frostfeldt G; Ahlberg G; Gustafsson G; Helmius G; Lindahl B; Nygren A; Siegbahn A; Swahn E; Venge P; Wallentin L
    J Am Coll Cardiol; 1999 Mar; 33(3):627-33. PubMed ID: 10080461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term management--the way forward?
    Wallentin L
    Clin Cardiol; 2000 Jan; 23 Suppl 1(Suppl):I13-7. PubMed ID: 10680039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
    Wallentin L; Lagerqvist B; Husted S; Kontny F; Ståhle E; Swahn E
    Lancet; 2000 Jul; 356(9223):9-16. PubMed ID: 10892758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
    Lagerqvist B; Husted S; Kontny F; Ståhle E; Swahn E; Wallentin L;
    Lancet; 2006 Sep; 368(9540):998-1004. PubMed ID: 16980115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
    Wallentin L; Bergstrand L; Dellborg M; Fellenius C; Granger CB; Lindahl B; Lins LE; Nilsson T; Pehrsson K; Siegbahn A; Swahn E
    Eur Heart J; 2003 May; 24(10):897-908. PubMed ID: 12714021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group.
    Lindahl B; Venge P; Wallentin L
    J Am Coll Cardiol; 1997 Jan; 29(1):43-8. PubMed ID: 8996293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low molecular weight heparin for treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin sodium) in acute myocardial infarction.
    Kakkar VV; Iyengar SS; De Lorenzo F; Hargreaves JR; Kadziola ZA;
    Indian Heart J; 2000; 52(5):533-9. PubMed ID: 11256775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety and efficacy of dalteparin administration for elective percutaneous interventions in patients pre-treated with aspirin and ticlopidine].
    Dudek D; Chyrchel M; Legutko J; Bartuś S; Rzeszutko L; Dubiel JS
    Przegl Lek; 2004; 61(12):1301-4. PubMed ID: 15850317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study).
    Wallentin L; Husted S; Kontny F; Swahn E
    Am J Cardiol; 1997 Sep; 80(5A):61E-63E. PubMed ID: 9296473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.